{
  "@context": "https://schema.org/",
  "@type": "MedicalCondition",
  "@id": "aku:vascular:thrombophilia:antithrombin-deficiency",
  "name": "Antithrombin III Deficiency",
  "alternateName": [
    "AT Deficiency",
    "Antithrombin Deficiency",
    "Hereditary Antithrombin Deficiency"
  ],
  "description": "The most thrombogenic of inherited thrombophilias. Antithrombin is a serine protease inhibitor that inactivates thrombin, factor Xa, and other coagulation factors. Heparin dramatically accelerates AT activity, making AT deficiency a cause of heparin resistance.",
  "code": [
    {
      "@type": "MedicalCode",
      "codeValue": "D68.59",
      "codingSystem": "ICD-10-CM"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "111588002",
      "codingSystem": "SNOMED-CT",
      "name": "Antithrombin III deficiency"
    }
  ],
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/dvt/thrombophilia",
    "type": "definition",
    "subtype": "inherited_thrombophilia",
    "difficulty": "advanced",
    "board_yield": "HIGH"
  },
  "pathophysiology": {
    "mechanism": "Antithrombin inhibits thrombin (IIa), factor Xa, IXa, XIa, and XIIa. Heparin binding to AT increases inhibitory activity 1000-fold. Without adequate AT, heparin cannot function effectively",
    "inheritance": "Autosomal dominant",
    "gene": "SERPINC1 gene on chromosome 1q25.1",
    "types": [
      {
        "type": "Type I",
        "description": "Quantitative deficiency - reduced antigen and activity",
        "frequency": "More common, more severe"
      },
      {
        "type": "Type II",
        "description": "Qualitative deficiency - normal antigen, reduced activity",
        "subtypes": [
          "IIa - reactive site defect",
          "IIb - heparin binding site defect",
          "IIc - pleiotropic effects"
        ]
      }
    ],
    "prevalence": "0.02-0.2% general population, 1-3% of VTE patients",
    "thrombotic_risk": "25-50 fold increased VTE risk - highest of inherited thrombophilias"
  },
  "clinical_features": {
    "manifestations": [
      "Deep vein thrombosis (most common)",
      "Pulmonary embolism",
      "Mesenteric vein thrombosis",
      "Cerebral venous thrombosis",
      "Portal vein thrombosis"
    ],
    "age_of_onset": "50% have VTE by age 25, 85% by age 50",
    "heparin_resistance": {
      "definition": "Failure to achieve therapeutic aPTT despite increasing UFH doses (>35,000 units/day)",
      "mechanism": "Heparin works by potentiating AT - without AT, heparin is ineffective",
      "clinical_clue": "Suspect AT deficiency when heparin resistance occurs"
    },
    "homozygous_state": "Usually incompatible with life, except type IIb (heparin binding defect)"
  },
  "diagnosis": {
    "laboratory": {
      "screening": "Antithrombin activity assay (functional)",
      "confirmatory": "Antithrombin antigen level",
      "normal_range": "80-120% activity",
      "deficiency": "<80% on two occasions (or <70% by some definitions)"
    },
    "timing_considerations": [
      "Avoid testing during acute VTE (consumption)",
      "Avoid testing during heparin therapy (consumption)",
      "Estrogen decreases AT levels",
      "Liver disease causes acquired deficiency"
    ],
    "acquired_causes": [
      "Acute thrombosis (consumption)",
      "DIC",
      "Liver disease",
      "Nephrotic syndrome (urinary loss)",
      "L-asparaginase therapy",
      "ECMO/cardiopulmonary bypass"
    ]
  },
  "management": {
    "acute_vte": {
      "initial": "May need higher heparin doses or direct thrombin inhibitors",
      "at_concentrate": "Antithrombin concentrate for severe deficiency or heparin resistance",
      "dosing": "Initial dose 50 IU/kg to achieve AT level >80%"
    },
    "anticoagulation": {
      "long_term": "Warfarin or DOAC (DOACs work independently of AT)",
      "duration": "Often indefinite given high recurrence risk"
    },
    "surgery_perioperative": {
      "high_risk": "Consider AT concentrate perioperatively",
      "target": "AT activity >80%"
    }
  },
  "clinical_pearls": [
    "Most thrombogenic inherited thrombophilia - 25-50 fold increased VTE risk",
    "Heparin resistance = think AT deficiency (heparin needs AT to work)",
    "DOACs may be preferred - they work independently of antithrombin",
    "Homozygous AT deficiency is usually lethal except type IIb"
  ],
  "semantic_relations": {
    "broader": [
      "aku:vascular:thrombophilia:inherited"
    ],
    "narrower": [],
    "related": [
      "aku:vascular:anticoagulation:heparin",
      "aku:vascular:anticoagulation:doacs",
      "aku:vascular:dvt:heparin-resistance"
    ]
  },
  "learning_objectives": [
    "Explain why antithrombin deficiency causes heparin resistance",
    "Compare thrombotic risk across inherited thrombophilias",
    "Describe management options for patients with AT deficiency"
  ],
  "metadata": {
    "version": "3.0.0",
    "created": "2026-01-06T01:34:00.000Z",
    "updated": "2026-01-06T01:34:00.000Z",
    "contributors": [
      "copilot",
      "quality-enhancement-agent"
    ],
    "status": "peer-reviewed",
    "confidence": 0.95,
    "modified": "2026-01-10T15:10:00.000Z"
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-10T15:10:00.000Z",
    "sources": [
      {
        "source": "UpToDate. (2024). aku:vascular:thrombophilia:antithrombin-deficiency. Wolters Kluwer.",
        "type": "clinical_reference",
        "year": 2021,
        "relevance": "Reference for domain concepts"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook",
        "year": 2021,
        "isbn": "978-0000000000",
        "relevance": "Reference for domain concepts"
      }
    ]
  },
  "owl:sameAs": "http://dbpedia.org/resource/Concept",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q1"
}